An alphavirus vector overcomes the presence of neutralizing antibodies and elevated numbers of Tregs to induce immune responses in humans with advanced cancer - Test2 - elhamkhani - TriplyDB

An alphavirus vector overcomes the presence of neutralizing antibodies and elevated numbers of Tregs to induce immune responses in humans with advanced cancer

An alphavirus vector overcomes the presence of neutralizing antibodies and elevated numbers of Tregs to induce immune responses in humans with advanced cancer

http://www.wikidata.org/entity/Q34090155

about

Alphavirus-based vaccines Novel recombinant alphaviral and adenoviral vectors for cancer immunotherapy Replicon RNA Viral Vectors as Vaccines Viral vector-based influenza vaccines.High efficiency of alphaviral gene transfer in combination with 5-fluorouracil in a mouse mammary tumor model.Improved cytotoxic T-lymphocyte immune responses to a tumor antigen by vaccines co-expressing the SLAM-associated adaptor EAT-2.Virus-vectored influenza virus vaccines.Strengthened tumor antigen immune recognition by inclusion of a recombinant Eimeria antigen in therapeutic cancer vaccination.Viral vector-based therapeutic cancer vaccines Combination of alphavirus replicon particle-based vaccination with immunomodulatory antibodies: therapeutic activity in the B16 melanoma mouse model and immune correlates.Neoadjuvant administration of Semliki Forest virus expressing interleukin-12 combined with attenuated Salmonella eradicates breast cancer metastasis and achieves long-term survival in immunocompetent mice.Lack of interference with immunogenicity of a chimeric alphavirus replicon particle-based influenza vaccine by preexisting antivector immunity Phase I safety and immunogenicity evaluations of an alphavirus replicon HIV-1 subtype C gag vaccine in healthy HIV-1-uninfected adults.Novel adenoviral vector induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients Polyclonal immune responses to antigens associated with cancer signaling pathways and new strategies to enhance cancer vaccines Co-delivery of antigen and IL-12 by Venezuelan equine encephalitis virus replicon particles enhances antigen-specific immune responses and antitumor effects.Targeting Carcinoembryonic Antigen with DNA Vaccination: On-Target Adverse Events Link with Immunologic and Clinical Outcomes.Potential targets for pancreatic cancer immunotherapeutics.Genetic cancer vaccines: current status and perspectives.Cancer vaccines targeting carcinoembryonic antigen: state-of-the-art and future promise.A development that may evolve into a revolution in medicine: mRNA as the basis for novel, nucleotide-based vaccines and drugs RNA-based drugs and vaccines.Self-replicating alphavirus RNA vaccines.Designing effective vaccines for colorectal cancer.RNA-based viral vectors.Alphavirus-based vaccines in melanoma: rationale and potential improvements in immunotherapeutic combinations.Anti-tumor effect of the alphavirus-based virus-like particle vector expressing prostate-specific antigen in a HLA-DR transgenic mouse model of prostate cancer.Viral and Synthetic RNA Vector Technologies and Applications.Oncolytic Alphaviruses in Cancer Immunotherapy.Semliki Forest virus biodistribution in tumor-free and 4T1 mammary tumor-bearing mice: a comparison of transgene delivery by recombinant virus particles and naked RNA replicon.Bridging infectious disease vaccines with cancer immunotherapy: a role for targeted RNA based immunotherapeutics.Preliminary Evaluation of a Bunyavirus Vector for Cancer Immunotherapy.Trial Watch: DNA vaccines for cancer therapy.Alphavirus-Based Vaccines.Semliki Forest VirusExpression System The Journey of Virus Engineered Dendritic Cells From Bench to Bedside: A Bumpy Road

P2860

Q26994724-96A957DD-A923-4DE3-A763-B1E394130843 Q27013586-388A6210-33FF-4606-877B-1437ABDA3449 Q28076639-1D32812D-1F3E-4CD5-8730-328B72541FBF Q30390938-FCABE9E4-A5F0-4D61-A072-B800B3F85410 Q33828697-BF56C520-F78C-46F7-B565-64B45E295BAF Q34080911-027B3BF1-5016-46FA-BADD-C5FF9C8182D7 Q34102268-6C3C4DAA-D91D-4CF5-A824-AC202C623BE8 Q35209044-F962DFE6-A608-4F2F-AB3B-F0D48CA7B4A3 Q35515080-3ECB285B-9721-409E-9E64-EE7B5A90DCEF Q35527105-9958FC05-21AA-44BE-AFFB-C888F124996D Q35766493-449144C4-73A8-4BE5-8532-0F6F727947A0 Q36086236-AFBC7D7F-BF89-4647-9709-117833B54254 Q36362287-7D9B24C3-BE37-4F9B-93FD-65A2FAFB2421 Q37068071-F00027AD-477D-442F-91D0-9194096B8570 Q37173925-84D50F80-39C0-47EE-A3F9-DBA6CF5C91B3 Q37416110-40981922-4B35-4745-947E-9CC4C20B5665 Q37671730-49C472B9-C029-4174-8DAE-91D085400FC3 Q37861220-2C586CC5-7B5E-47C8-85BC-F408FAD94AED Q38009352-4FFDA4CF-8C87-43B6-8B7F-1FC07B92DF89 Q38113267-4621F50C-F817-4BE9-BE92-BBC3825466DC Q38206520-C9AA79A4-69A9-4B92-AA03-C772745B8E4D Q38249163-C6E47C66-A628-41A0-A12B-AFF3E3AA559B Q38255634-AFB5E5F5-5D0C-4287-AFCD-A958040ABA25 Q38260051-688BD302-A9A6-485C-AFF5-180C2A6A0D50 Q38266413-2E77F460-DCD4-4606-90ED-749B9D70A7AD Q38574574-97018466-D0C7-43DB-BC25-15E164980476 Q38839675-EA82898B-3B4B-4D41-8B4F-4AB44DD8B432 Q38885624-91E3A74D-F165-4CF1-B2ED-9EEADAD04832 Q39247874-474D5ED1-743B-4F23-8897-05E09030E1BA Q39327107-A004E3DA-9211-4E15-9C09-800088B908ED Q39829133-E35842E2-CF43-47B1-A27F-3F85D1AABC84 Q40151111-58C694F0-6D47-42F3-A405-1A4EA734249A Q42552005-2E9E8A03-48A0-4848-8AFC-FE8084A48C82 Q50870504-34A61305-5E13-4C18-9903-DB4E2E9FBDE3 Q56922178-CF02D591-0C03-48B9-AFD5-4539F83E91A8 Q58750585-CBD1D29D-7A51-4324-8A94-A400E70F479B

P2860

An alphavirus vector overcomes the presence of neutralizing antibodies and elevated numbers of Tregs to induce immune responses in humans with advanced cancer

http://www.wikidata.org/entity/Q34090155

description

2010 nî lūn-bûn

@nan

2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

An alphavirus vector overcomes ...... in humans with advanced cancer

@ast

An alphavirus vector overcomes ...... in humans with advanced cancer

@en

An alphavirus vector overcomes ...... in humans with advanced cancer

@nl

type

label

An alphavirus vector overcomes ...... in humans with advanced cancer

@ast

An alphavirus vector overcomes ...... in humans with advanced cancer

@en

An alphavirus vector overcomes ...... in humans with advanced cancer

@nl

prefLabel

An alphavirus vector overcomes ...... in humans with advanced cancer

@ast

An alphavirus vector overcomes ...... in humans with advanced cancer

@en

An alphavirus vector overcomes ...... in humans with advanced cancer

@nl

P1433

Q34090155-B658455D-F3AA-440A-86D0-41D451008F6C

P1476

Q34090155-4904C886-3483-4649-9CE8-6A233FB3C682

P2093

Q34090155-38842395-630E-4837-8AB2-5AA4E3E9A1A8

Q34090155-488C58A5-6EA8-41C8-AF02-DB395671FACD

Q34090155-7601E7A5-DF22-476B-A94C-C40DE67E2271

Q34090155-8DB7B7E5-0172-4D0D-9340-7730AED7DEC2

Q34090155-8F909E28-9862-450C-A488-A57C10EE30E2

Q34090155-99D3B69B-2BCA-4329-A044-9C6FB081A579

Q34090155-9F5404B7-438E-4BA9-823D-7BE79C106C67

Q34090155-B4DBD6F2-5928-4800-8116-F99152804BAC

Q34090155-BDACF0F9-1D85-4210-BBE4-15F2CF407726

Q34090155-C7344CAB-1767-4B3B-967B-EB48B64BB496

P2860

Q34090155-0BFA5E88-0297-4D8F-8AD7-6CCB3EEE0D0B

Q34090155-0C1283EA-7DD0-42B1-B091-06F8375F79FE

Q34090155-1A7145A4-623D-4BAE-B045-8CD64582D7A4

Q34090155-303599C7-6C4F-48CC-B9F9-4AA7AD2B833D

Q34090155-33F4F891-AAB9-40D9-B660-3FC32F0A192B

Q34090155-3DFB8392-D042-4F5D-976F-77AB6317DB21

Q34090155-450A51C7-1FDA-4429-8171-7A06E3829E05

Q34090155-485C4D43-5492-41CC-B4E8-75EF7A053769

Q34090155-6112D54F-757F-422A-BCDD-CC53F5DB2A97

Q34090155-6D025B44-35EE-4928-829B-BF64A6F54F27

P304

Q34090155-DC8CC854-64FA-4490-95E1-9AC0BCD36DA9

P31

Q34090155-A9A30679-E506-4D56-BDF1-E35FF2307BC3

P356

Q34090155-B9F20673-9C7E-470D-929A-59D7CD5BE6CC

P407

Q34090155-95E271D0-BCEC-4ACE-B219-2C9C0FF6F511

P433

Q34090155-AB5E9E6A-FDF5-40AA-B57F-682D25DC491D

P478

Q34090155-6264CFA3-94DD-4CED-A576-C2411F98DE65

P577

Q34090155-531481E8-59A2-4018-B074-A5E6531AAAD8

P5875

Q34090155-8BB3C4F4-2D14-43FD-8CBD-5E78FD7728F1

P698

Q34090155-89960AF0-B295-49FE-829B-2F0A680CB395

P921

Q34090155-7FD3A7AC-3D61-4612-B395-C0FC37AF19C5

P932

Q34090155-625061C5-4969-424A-8CB0-ADE90E5C64BD

P356

P1433

Journal of Clinical Investigation

P1476

An alphavirus vector overcomes ...... in humans with advanced cancer

@en

P2093

Amy C Hobeika

http://www.w3.org/2001/XMLSchema#string

Bolyn Hubby

http://www.w3.org/2001/XMLSchema#string

Bruce K Burnett

http://www.w3.org/2001/XMLSchema#string

Donna Niedzwiecki

http://www.w3.org/2001/XMLSchema#string

Gayathri R Devi

http://www.w3.org/2001/XMLSchema#string

H Kim Lyerly

http://www.w3.org/2001/XMLSchema#string

Jonathan Smith

http://www.w3.org/2001/XMLSchema#string

Michael A Morse

http://www.w3.org/2001/XMLSchema#string

Peter Berglund

http://www.w3.org/2001/XMLSchema#string

Sarah Negri

http://www.w3.org/2001/XMLSchema#string

P2860

Alphavirus replicon particles containing the gene for HER2/neu inhibit breast cancer growth and tumorigenesis.

The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells

Regulatory T cells in cancer.

Carcinoembryonic antigen as a target for therapeutic anticancer vaccines: a review.

Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy.

Alphavirus vectors and vaccination.

Naturally-occurring CD4+CD25+ immunoregulatory T cells: central players in the arena of peripheral tolerance.

Escape from immunotherapy: possible mechanisms that influence tumor regression/progression.

P304

3234-3241

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1172/JCI42672

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

120

http://www.w3.org/2001/XMLSchema#string

P577

2010-08-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

45461867

http://www.w3.org/2001/XMLSchema#string

P698

20679728

http://www.w3.org/2001/XMLSchema#string

P921

P932

2929723

http://www.w3.org/2001/XMLSchema#string